Cristina R. Ferrone

Cedars-Sinai Medical Center

Full Professor(heuristic)

Pancreatic and Hepatic Oncology Research · Oncology

h-index80

i10-index243

Publications733

Citations27,502

Grants

7 total · 0 active

NIH #1R03CA280302-01

Tumor downstaging with small molecule therapeutics to enhance Uveal Melanoma metastasis eradication by B7-H3 CAR T cells

Amount: $167K
Period: 2023-09-20 → 2025-08-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #7R03CA253319-02

Potential role of brachyury in HLA class I antigen processing machinery component downregulation in chordoma cells

Amount: $77K
Period: 2020-09-01 → 2024-11-30
PIs: 2
Est. capacity / PI: ~0 students

NIH #1R03CA249542-01A1

B7-H3 CAR T cell-based immunotherapy combined with Losartan to counteract desmoplasia for the treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

Amount: $167K
Period: 2021-05-01 → 2023-04-30
PIs: 2
Est. capacity / PI: ~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

7 total · 0 active

NIH #1R03CA280302-01

Tumor downstaging with small molecule therapeutics to enhance Uveal Melanoma metastasis eradication by B7-H3 CAR T cells

Amount: $167K
Period: 2023-09-20 → 2025-08-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #7R03CA253319-02

Potential role of brachyury in HLA class I antigen processing machinery component downregulation in chordoma cells

Amount: $77K
Period: 2020-09-01 → 2024-11-30
PIs: 2
Est. capacity / PI: ~0 students

NIH #1R03CA249542-01A1

B7-H3 CAR T cell-based immunotherapy combined with Losartan to counteract desmoplasia for the treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

Amount: $167K
Period: 2021-05-01 → 2023-04-30
PIs: 2
Est. capacity / PI: ~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5R03CA231766-02

IL-15 TRiKES-based specific immunotherapy of pancreatic ductal adenocarcinoma

Amount: $80K
Period: 2018-08-01 → 2021-07-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #1R03CA231766-01

IL-15 TRiKES-based specific immunotherapy of pancreatic ductal adenocarcinoma

Amount: $97K
Period: 2018-08-01 → 2020-07-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5R21CA164756-02

Grp94 targeted therapy for pancreatic ductal adenocarcinoma

Amount: $220K
Period: 2013-09-11 → 2016-08-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #1R21CA164756-01A1

Grp94 targeted therapy for pancreatic ductal adenocarcinoma

Amount: $189K
Period: 2013-09-11 → 2015-08-31
PIs: 2
Est. capacity / PI: ~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0024

PageRank within Oncology co-authorship network

Explore collaboration map

Admission Signals

New paper: Data from Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors2026-06-19

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0002-6295-1085

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 124

Data from Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors
2026-06-19
Supplementary Figures 1-8 from Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors
2026-06-19
Supplementary Tables 1 from Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors
2026-06-19
Figure S1 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
2026-06-17
Figure S7 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
2026-06-17
Figure S8 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
2026-06-17
Figure S4 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
2026-06-17
Figure S2 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
2026-06-17
Figure S11 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
2026-06-17
Figure S10 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
2026-06-17
Figure S5 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
2026-06-17
Figure S3 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
2026-06-17
Figure S9 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
2026-06-17
Figure S6 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
2026-06-17
AI-Driven Pathology and Blood-Based Biomarkers: A Golden Opportunity to Democratize Precision Oncology
Cancer Discovery · 2026-04-20
Neoadjuvant Stereotactic Body Radiotherapy plus Immune Therapy Favorably Remodels the Hepatocellular Carcinoma Tumor Microenvironment
Clinical Cancer Research · 2026-04-15
Management of splanchnic venous thrombosis after splenectomy in hematologic diseases: systematic review, meta-analysis, and consensus guidelines
International Journal of Surgery · 2025-12-19
Long-term Outcomes of Spleen-preserving Distal Pancreatectomy With or Without Preservation of Splenic Vessels
Annals of Surgery · 2025-12-11 · 1 citations
rs10204525 binding to miR-4717-3p modulates PD-1 expression and predicts the development of immune-related adverse events in patients with advanced cancer treated with anti-PD-1/PD-L1 therapy
Journal for ImmunoTherapy of Cancer · 2025-12-01 · 1 citations
The São Paulo International Consensus on Minimally Invasive Pancreatic Surgery for Cancer
HPB · 2025-11-22 · 3 citations

Open author page on OpenAlex →